Premium
Early relapse after high‐dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high‐risk disease in multiple myeloma
Author(s) -
Bygrave Ceri,
Pawlyn Charlotte,
Davies Faith,
Craig Zoe,
Cairns David,
Hockaday Anna,
Jenner Matthew,
Cook Gordon,
Drayson Mark,
Owen Roger,
Gregory Walter,
Morgan Gareth,
Jackson Graham,
Kaiser Martin
Publication year - 2021
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.16793
Subject(s) - medicine , multiple myeloma , melphalan , oncology , stem cell , disease , transplantation , overall survival , surgery , biology , genetics
Summary Predicting patient outcome in multiple myeloma remains challenging despite the availability of standard prognostic biomarkers. We investigated outcome for patients relapsing early from intensive therapy on NCRI Myeloma XI. Relapse within 12 months of autologous stem cell transplant was associated with markedly worse median progression‐free survival 2 (PFS2) of 18 months and overall survival (OS) of 26 months, compared to median PFS2 of 85 months and OS of 91 months for later relapsing patients despite equal access to and use of subsequent therapies, highlighting the urgent need for improved outcome prediction and early intervention strategies for myeloma patients.